FDA approves Xadago for Parkinson’s patients

22-Mar-2017

Xadago (safinamide) is first NCE approved in the USA for PD patients with motor fluctuations in a decade

The FDA has approved the use of Xadago (safinamide) for the treatment of Parkinson’s disease as add-on therapy to levodopa/carbidopa.

Xadago was developed by Newron Pharmaceuticals and its partners Zambon and US WorldMeds.

Newron Pharmaceuticals is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central nervous system (CNS) and pain.

US WorldMeds is a specialty pharmaceutical company dedicated to developing, licensing and commercializing unique and significant specialty pharmaceuticals that address unmet medical needs or overcome limitations of existing products.

This first new treatment for a decade represents an important addition to the treatment choices for patients.

Zambon is an Italian, multinational pharmaceutical and fine-chemical company established in three therapeutic areas: respiratory, pain and women’s care.

Ravi Anand, Newron’s CMO, said: “Xadago significantly improves ON time, OFF time and Parkinsonism compared to standard of care – without increasing time spent with troublesome dyskinesia in patients experiencing motor fluctuations while on optimised levodopa/carbidopa therapy.”

“Additionally, the onset of improvement of motor fluctuations occurred early in treatment.”

Sign up for your free email newsletter

Charlotte Keywood, Global Head of Research and Development at Zambon, said: "This first new treatment for a decade represents an important addition to the treatment choices for patients with Parkinson's.”

Companies